Zymoflam D Tablet is a combination pharmaceutical formulation containing Trypsin (48mg), Bromelain (90mg), Rutoside (100mg), and Diclofenac (50mg), designed to provide effective anti-inflammatory, analgesic, and fibrinolytic benefits. Trypsin and Bromelain are proteolytic enzymes that facilitate the breakdown of proteins, thereby reducing inflammation and promoting the resolution of edema and hematoma in acute injuries. Rutoside, a bioflavonoid, enhances capillary strength and reduces capillary permeability, contributing to decreased swelling and improved microcirculation. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), exerts potent analgesic and anti-inflammatory effects by inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin synthesis. The synergistic action of these components makes Zymoflam D effective in managing conditions such as musculoskeletal injuries, postoperative inflammation, and soft tissue trauma. It is indicated for the relief of pain and inflammation associated with sprains, strains, contusions, and post-surgical recovery. Zymoflam D should be used under medical supervision, considering contraindications such as hypersensitivity to NSAIDs, peptic ulcer disease, and bleeding disorders. The dosage and duration of therapy must be tailored to individual patient needs to maximize therapeutic outcomes while minimizing potential adverse effects.